Delivery Order SPE2DB20D1109-SPE2DB24FP64B

Award Date 8/5/24
Potential Completion Date 8/6/24
Potential Value $13K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products to the Defense Logistics Agency (DLA). The $3,800.21 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of February 26, 2025 and is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The $31,917.67 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a completion date of November 8, 2024 and is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,770.38 fixed-price delivery order is for DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has an ultimate completion date of November 18, 2024 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery...
This federal contract award is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The $19,281.50 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of December 5, 2024 and is not designated as a set-aside requirement. Amerisourcebergen holds a significant $999,999,999 Indefinite...
This federal contract award is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products to the Defense Logistics Agency (DLA). The $39,226.24 firm fixed-price contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on December 3, 2024 with an ultimate completion date of December 4, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $30,041.32 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on June 10, 2025 with a completion date of June 11, 2025. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC)...
This federal contract award is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products to the Defense Logistics Agency (DLA). The $6,278.46 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., on February 14, 2024, with a completion date of February 15, 2024. Amerisourcebergen Drug Corp holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the...
This federal contract award, issued by the Defense Logistics Agency (DLA), was granted to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,638.01 firm fixed-price delivery order is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a specialty pharmaceutical product. The contract has an ultimate completion date of June 11, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,304.72 firm fixed-price delivery order is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a specialty pharmaceutical product. The contract has an ultimate completion date of May 16, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $24,703.58 firm fixed-price delivery order is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a specialty pharmaceutical product. The contract has an ultimate completion date of November 5, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
  • SPE2DB20D1109
    Indefinite Delivery Contract
  • SPE2DB20D1109-SPE2DB24FP64B
    Delivery Order

This federal contract award is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products to the Defense Logistics Agency (DLA). The $12,633.87 fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on August 5, 2024 with a completion date of August 6, 2024. The contract is not designated with any set-aside requirements.

AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation through May 2024, covering similar medical products and prescription drugs.

Generated 2/27/25, 11:40 AM